Literature DB >> 2984985

Structure-activity studies on phosphonoacetate.

J C Mao, E R Otis, A M von Esch, T R Herrin, J S Fairgrieve, N L Shipkowitz, R G Duff.   

Abstract

Phosphonoacetic acid is a selective antiherpesvirus agent. More than 100 congeners of phosphonoacetic acid were evaluated in vitro and in vivo to understand structure-activity relationships in the hope of designing a superior analog. Results showed that the antiherpesvirus activity had highly specific structural requirements. Neither the carboxylic nor the phosphono groups could be replaced. The distance between these two groups is important. Increase of this distance caused complete loss of activity. However, if this distance was maintained, the addition of groups to the methylene carbon resulted in a reduction, but not loss, of activity. On the other hand, decrease of the carbon chain to formic acid did not deteriorate its antiherpes activity. All analogs tested had lower activity than the parent compound. However, some compounds with decreased activity in vitro appeared to have favorable pharmacological properties in vivo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984985      PMCID: PMC176237          DOI: 10.1128/AAC.27.2.197

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid.

Authors:  W C Summers; G Klein
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

2.  Effect of phosphonoacetate on Marek's disease virus replication.

Authors:  L F Lee; K Nazerian; S S Leinbach; J M Reno; J A Boezi
Journal:  J Natl Cancer Inst       Date:  1976-04       Impact factor: 13.506

3.  Phosphonoacetic acid-resistant herpes simplex virus infection in hairless mice.

Authors:  R J Klein; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

4.  Phosphonoacetic acid in the treatment of experimental herpes simplex keratitis.

Authors:  D D Gerstein; C R Dawson; J O O
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

5.  Aspartate transcarbamylase. Interaction with the transition state analogue N-(phosphonacetyl)-L-aspartate.

Authors:  K D Collins; G R Stark
Journal:  J Biol Chem       Date:  1971-11       Impact factor: 5.157

6.  Synthesis of herpes simplex virus, vaccinia virus, and adenovirus DNA in isolated HeLa cell nuclei. I. Effect of viral-specific antisera and phosphonoacetic acid.

Authors:  A Bolden; J Aucker; A Weissbach
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

7.  Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid.

Authors:  E S Huang
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

8.  Mode of inhibition of herpes simplex virus DNA polymerase by phosphonoacetate.

Authors:  J C Mao; E E Robishaw
Journal:  Biochemistry       Date:  1975-12-16       Impact factor: 3.162

9.  Mechanism of phosphonoacetate inhibition of herpesvirus-induced DNA polymerase.

Authors:  S S Leinbach; J M Reno; L F Lee; A F Isbell; J A Boezi
Journal:  Biochemistry       Date:  1976-01-27       Impact factor: 3.162

10.  Suppression of herpes simplex virus infection by phosphonoacetic acid.

Authors:  N L Shipkowitz; R R Bower; R N Appell; C W Nordeen; L R Overby; W R Roderick; J B Schleicher; A M Von Esch
Journal:  Appl Microbiol       Date:  1973-09
View more
  2 in total

1.  Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes.

Authors:  F C Szoka; C J Chu
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

2.  Route to α-Aryl Phosphonoacetates: Useful Synthetic Precursors in the Horner-Wadsworth-Emmons Olefination.

Authors:  Kelsey F VanGelder; Melinda Wang; Marisa C Kozlowski
Journal:  J Org Chem       Date:  2015-10-03       Impact factor: 4.354

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.